Purpose <p>Chemoradiotherapy (CRT) combined with anti-PD-1 for locally advanced esophageal squamous cell carcinoma (ESCC) has shown promising efficacy but lack the predictive biomarkers to identify patients who could benefit from this therapy. The predictive value of serum cytokines in ESCC patients remains unclear. We aimed to identify cytokine-based biomarkers for treatment response and survival in this setting.</p> Experimental Design <p>Exploratory…
Serum cytokines predict response and survival in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD-1 antibody: analyses of two phase II clinical trials
Journal for ImmunoTherapy of Cancer | | Chen, B., Chen, J., Wang, S., Bai, K., Li, Z., Chen, B., Wang, R., Cheng, X., Gao, Y., Yi, C., Cen, P., Li, S., Dragomir, M. P., Zhu, Y., Li, Q., Yang, H., Xi, M.
Topics: blood-cancer, cervical-cancer, immunotherapy, targeted-therapy, chemotherapy, radiation, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer